308 related articles for article (PubMed ID: 21200420)
21. A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by L. braziliensis.
Celes FS; Barud HS; Viana SM; Borba PB; Machado PRL; Carvalho EM; de Oliveira CI
Acta Trop; 2022 Jan; 225():106192. PubMed ID: 34662548
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis.
Ware JM; O'Connell EM; Brown T; Wetzler L; Talaat KR; Nutman TB; Nash TE
Clin Infect Dis; 2021 Oct; 73(7):e2457-e2562. PubMed ID: 33124666
[TBL] [Abstract][Full Text] [Related]
24. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.
van Henten S; Tesfaye AB; Abdela SG; Tilahun F; Fikre H; Buyze J; Kassa M; Cnops L; Pareyn M; Mohammed R; Vogt F; Diro E; van Griensven J
PLoS Negl Trop Dis; 2021 May; 15(5):e0009460. PubMed ID: 34048461
[TBL] [Abstract][Full Text] [Related]
25. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
26. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis.
Sousa AQ; Frutuoso MS; Moraes EA; Pearson RD; Pompeu MM
Clin Infect Dis; 2011 Oct; 53(7):693-5. PubMed ID: 21890773
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
28. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis.
Joseph S; Whitman TJ; Buckner FS; Cogen AL
Am J Trop Med Hyg; 2021 May; 105(1):142-143. PubMed ID: 33970891
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility to Miltefosine in Brazilian Clinical Isolates of
Espada CR; Ribeiro-Dias F; Dorta ML; Pereira LIA; Carvalho EM; Machado PR; Schriefer A; Yokoyama-Yasunaka JKU; Coelho AC; Uliana SRB
Am J Trop Med Hyg; 2017 Mar; 96(3):656-659. PubMed ID: 28070006
[No Abstract] [Full Text] [Related]
32. Trial of oral miltefosine for visceral leishmaniasis.
Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
[TBL] [Abstract][Full Text] [Related]
33. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Ollech A; Solomon M; Horev A; Reiss-Huss S; Ben-Amitai D; Zvulunov A; Friedland R; Atar-Snir V; Pessach-Molcho V; Barzilai A; Greenberger S
Acta Derm Venereol; 2020 Nov; 100(18):adv00322. PubMed ID: 33205828
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Ollech A; Solomon M; Horev A; Reiss-Huss S; Ben-Amitai D; Zvulunov A; Friedland R; Atar-Snir V; Molho-Pessach V; Barzilai A; Greenberger S
Acta Derm Venereol; 2020 Oct; 100(18):adv00322. PubMed ID: 33074340
[TBL] [Abstract][Full Text] [Related]
37. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
38. Natural Resistance of
Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
[TBL] [Abstract][Full Text] [Related]
39. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
[TBL] [Abstract][Full Text] [Related]
40. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
